Vera Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vera Therapeutics's earnings have been declining at an average annual rate of -29.1%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-29.1%
Earnings growth rate
87.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -46.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late
Dec 22Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
Oct 07
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Oct 04Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Jul 22Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?
Jul 05Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Vera Therapeutics soars 16% on three new favorable view from analysts
Jun 08Revenue & Expenses Breakdown
How Vera Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -134 | 32 | 114 |
| 30 Jun 24 | 0 | -108 | 28 | 89 |
| 31 Mar 24 | 0 | -94 | 26 | 76 |
| 31 Dec 23 | 0 | -96 | 24 | 78 |
| 30 Sep 23 | 0 | -103 | 24 | 84 |
| 30 Jun 23 | 0 | -107 | 24 | 88 |
| 31 Mar 23 | 0 | -102 | 24 | 82 |
| 31 Dec 22 | 0 | -89 | 22 | 69 |
| 30 Sep 22 | 0 | -73 | 19 | 55 |
| 30 Jun 22 | 0 | -56 | 17 | 39 |
| 31 Mar 22 | 0 | -45 | 15 | 32 |
| 31 Dec 21 | 0 | -33 | 12 | 22 |
| 30 Sep 21 | 0 | -59 | 9 | 50 |
| 30 Jun 21 | 0 | -55 | 6 | 48 |
| 31 Mar 21 | 0 | -56 | 5 | 47 |
| 31 Dec 20 | 0 | -53 | 4 | 45 |
Quality Earnings: VERA is currently unprofitable.
Growing Profit Margin: VERA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VERA is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare VERA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VERA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: VERA has a negative Return on Equity (-46.49%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 14:55 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vera Therapeutics, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Liisa Bayko | Evercore ISI |
| Paul Choi | Goldman Sachs |